Brinton ties up with Scholl Wellness Company

Brinton Pharmaceuticals enters exclusive sales and distribution rights of Scholl foot care products including Krack cream

DCGI approves Themis Medicare's Viralex for Covid-19 treatment

Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections

CryptoRelief partners with IIT Madras to establish wastewater-based research centre

Scientists worldwide have started employing wastewater analysis as an efficient and cost-effective approach for assessing the dynamics of the virus in a population. Several scientific methods are being developed to rapidly decode the message carried by sewage

Amrita University launches wearable device for home monitoring of glucose and BP

Patients can use the wearable, non-invasive device to measure six body parameters including blood glucose, blood pressure, heart rate, blood oxygen, respiratory rate and 6-lead ECG, from the comfort of their home

Amneal enters U.S. biosimilars market with approval of Releukotm

First of three Amneal biosimilars expected for U.S. approval and launch in 2022

Biocon Biologics acquires Viatris’ biosimilar assets for up to US $ 3.3 billion

BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets

BDR Pharma launches enzalutamide in 160 mg strength

This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage

Prenetics Partners and ACON Bio launch Covid-19 antigen kits

Flowflex antigen test detects Covid-19, including the Omicron variant, in just 15 minutes with 98.8% accuracy

Experts say extended day prescription refills for hypertension can be a game-changer

The recently released WHO guideline on hypertension treatment (2021), recommends that patients with stable blood pressure can be asked to visit clinics at 3-6 month intervals as an important strategy to improve hypertension control

Prestige BioPharma’s Tuznue receives EU-GMP certification